These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 19075244)

  • 1. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection.
    Brooks DG; Ha SJ; Elsaesser H; Sharpe AH; Freeman GJ; Oldstone MB
    Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20428-33. PubMed ID: 19075244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Jekyll and Hyde Profile: Type 1 Interferon Signaling Plays a Prominent Role in the Initiation and Maintenance of a Persistent Virus Infection.
    Oldstone MB
    J Infect Dis; 2015 Jul; 212 Suppl 1(Suppl 1):S31-6. PubMed ID: 26116728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses against persistent viral infections: possible avenues for immunotherapeutic interventions.
    Fuse S; Molloy MJ; Usherwood EJ
    Crit Rev Immunol; 2008; 28(2):159-83. PubMed ID: 18540829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection.
    Brooks DG; Lee AM; Elsaesser H; McGavern DB; Oldstone MB
    J Exp Med; 2008 Mar; 205(3):533-41. PubMed ID: 18332180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.
    Klein S; Ghersi D; Manns MP; Prinz I; Cornberg M; Kraft ARM
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming CD4 Th1 Cell Fate Restrictions to Sustain Antiviral CD8 T Cells and Control Persistent Virus Infection.
    Snell LM; Osokine I; Yamada DH; De la Fuente JR; Elsaesser HJ; Brooks DG
    Cell Rep; 2016 Sep; 16(12):3286-3296. PubMed ID: 27653690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.
    Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH
    J Immunol; 2005 Mar; 174(6):3408-15. PubMed ID: 15749874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic intervention in cancer and chronic viral infections: antibody mediated manipulation of PD-1/PD-L1 interaction.
    Sakthivel P; Gereke M; Bruder D
    Rev Recent Clin Trials; 2012 Feb; 7(1):10-23. PubMed ID: 22023178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
    Burrack AL; Spartz EJ; Raynor JF; Wang I; Olson M; Stromnes IM
    Cell Rep; 2019 Aug; 28(8):2140-2155.e6. PubMed ID: 31433988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of B7-H1 enhances dendritic cell-mediated T cell response and antiviral immunity in HBV transgenic mice.
    Jiang W
    Vaccine; 2012 Jan; 30(4):758-66. PubMed ID: 22133510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 15. Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model.
    Lukens JR; Cruise MW; Lassen MG; Hahn YS
    J Immunol; 2008 Apr; 180(7):4875-84. PubMed ID: 18354211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
    Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
    Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus-triggered PTEN/β-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion.
    Sun Y; Yu M; Qu M; Ma Y; Zheng D; Yue Y; Guo S; Tang L; Li G; Zheng W; Wang M; Guo D; Li C
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G162-G173. PubMed ID: 31604033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
    Li L; Miao Q; Meng F; Li B; Xue T; Fang T; Zhang Z; Zhang J; Ye X; Kang Y; Zhang X; Chen Q; Liang X; Chen H; Zhang X
    Theranostics; 2021; 11(12):6033-6043. PubMed ID: 33897897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.